Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The transient outward potassium channel is a voltage-gated ion channel primarily responsible for the rapid, early repolarization phase (Phase 1) of the cardiac action potential (StatPearls, PMID: 30725637). It is composed of alpha subunits, most notably Kv4.3 (encoded by KCND3) and Kv4.2 (encoded by KCND2), which often associate with regulatory beta-subunits like KChIP2 to modulate channel kinetics (UniProt, P51777). In the heart, these channels help determine the characteristic notch of the action potential and influence the plateau phase, which is critical for proper excitation-contraction coupling (PubMed, PMID: 15618538). Dysregulation or genetic mutations in these channels are strongly linked to cardiac arrhythmias, including Brugada syndrome, atrial fibrillation, and heart failure-related electrical remodeling (PubMed, PMID: 21135220). Pharmacological modulation of the transient outward current (Ito) is a strategy in antiarrhythmic therapy, with drugs like vernakalant targeting these channels to terminate atrial arrhythmias (PubMed, PMID: 18413443). However, because these channels are also expressed in the central nervous system where they regulate neuronal firing patterns, therapeutic targeting requires careful consideration of potential neurological side effects (PubMed, PMID: 11518771).
Inhibition of the transient outward potassium current (Ito) to prolong the early phase of cardiac repolarization and modulate action potential duration.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient outward potassium channel (Ito).